According to ProHealth's cited reference (Sost MM et al., Nutrients, 2021), MicrobiomeX has been studied in clinical settings for its effect on shifting the gut microbiome toward butyrate-producing bacterial populations
Some patients need weekly injections at first, then switch to monthly maintenance based on lab levels and symptoms
At IV Lounge, the health and satisfaction of our customers always remain the main concern
SLU-PP-332 is a novel synthetic pan-agonist of the estrogen-related receptors (ERR, ERR, ERR), originally developed at Saint Louis University and characterised in recent pre-clinical literature as an exercise mimetic. It is widely studied in research models exploring mitochondrial biogenesis, fatty-acid oxidation, and metabolic endurance
While research indicates that it does not significantly impact growth hormone levels, IGF-1, or glucose metabolism, long-term studies on its safety are still limited